Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDXGet Rating) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $31.00 price objective on the stock.

A number of other equities analysts have also weighed in on SNDX. Zacks Investment Research upgraded Syndax Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, January 20th. The Goldman Sachs Group initiated coverage on Syndax Pharmaceuticals in a research note on Tuesday, February 15th. They set a buy rating and a $37.00 target price on the stock. StockNews.com initiated coverage on Syndax Pharmaceuticals in a research note on Thursday, March 31st. They set a hold rating on the stock. Finally, TheStreet upgraded Syndax Pharmaceuticals from a d rating to a c rating in a research note on Wednesday, March 9th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $27.17.

NASDAQ:SNDX opened at $17.71 on Monday. The company has a quick ratio of 21.68, a current ratio of 21.68 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average price is $16.67 and its two-hundred day moving average price is $17.78. The firm has a market capitalization of $974.32 million, a price-to-earnings ratio of 41.19 and a beta of 1.61. Syndax Pharmaceuticals has a 12-month low of $13.02 and a 12-month high of $22.96.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Rating) last released its quarterly earnings data on Tuesday, March 1st. The company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $2.49. Syndax Pharmaceuticals had a return on equity of 9.49% and a net margin of 17.84%. During the same period last year, the business earned ($0.44) EPS. Equities research analysts expect that Syndax Pharmaceuticals will post -2.84 EPS for the current year.

In other Syndax Pharmaceuticals news, insider Briggs Morrison sold 101,045 shares of the firm’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $17.45, for a total value of $1,763,235.25. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 106,553 shares of company stock worth $1,860,073 in the last three months. 7.60% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of SNDX. Invesco Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 83.6% in the 2nd quarter. Invesco Ltd. now owns 17,717 shares of the company’s stock valued at $305,000 after purchasing an additional 8,069 shares in the last quarter. Phoenix Holdings Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 90.9% in the 3rd quarter. Phoenix Holdings Ltd. now owns 210,000 shares of the company’s stock valued at $4,013,000 after purchasing an additional 100,000 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Syndax Pharmaceuticals in the 3rd quarter valued at $540,000. Los Angeles Capital Management LLC lifted its stake in shares of Syndax Pharmaceuticals by 30.2% in the 3rd quarter. Los Angeles Capital Management LLC now owns 22,844 shares of the company’s stock valued at $437,000 after acquiring an additional 5,300 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of Syndax Pharmaceuticals by 2.6% in the 3rd quarter. Swiss National Bank now owns 85,300 shares of the company’s stock valued at $1,630,000 after acquiring an additional 2,200 shares during the last quarter.

Syndax Pharmaceuticals Company Profile (Get Rating)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).

Further Reading

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.